<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03186404</url>
  </required_header>
  <id_info>
    <org_study_id>SPARE HF Pilot</org_study_id>
    <nct_id>NCT03186404</nct_id>
  </id_info>
  <brief_title>Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study</brief_title>
  <acronym>SPARE-HF</acronym>
  <official_title>Randomized Double Blind Placebo Controlled Trial of Statins for the Primary pREvention of Heart Failure in Patients With Cancer Receiving Anthracycline Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scarborough General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several&#xD;
      common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of&#xD;
      heart failure (HF). Current standard of care for preventing AC induced HF (AIHF) is cardiac&#xD;
      surveillance followed by initiation of treatment once HF is diagnosed. With this approach 89%&#xD;
      of patients fail to recover heart function and 46% will experience adverse cardiac events.&#xD;
      Therefore there is a need for effective preventive therapy to reduce the risk of AIHF. Based&#xD;
      on small human studies, animal studies, and our own pilot data, statins are an ideal class of&#xD;
      drug for this purpose.&#xD;
&#xD;
      We will conduct a pilot double blinded, placebo controlled, randomized controlled trial to&#xD;
      assess whether pre-treatment with statins before AC can prevent heart dysfunction. Eligible&#xD;
      patients with cardiovascular risk factors scheduled to receive AC will be recruited. They&#xD;
      will be randomized to statin therapy or placebo and followed until the end of cancer&#xD;
      treatment. Primary outcome is the difference in cardiac MRI-determined left ventricular&#xD;
      ejection fraction between pre-AC and end of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN: This is a double blind, placebo controlled randomized controlled trial (RCT).&#xD;
      We will also use stratification to ensure that the proportion of patients with different&#xD;
      malignancies is balanced between the study arms.&#xD;
&#xD;
      PATIENT RECRUITMENT: Patients will be recruited from respective oncology clinics at Princess&#xD;
      Margaret Hospital, Mount Sinai Hospital, St. Michael's Hospital, Sunnybrook Health Sciences&#xD;
      Centre and Scarborough General Hospital.&#xD;
&#xD;
      INTERVENTION: Patients will receive treatment with 40mg/day of atorvastatin or placebo&#xD;
      started 2-10 days prior to the initiation of AC and continued for up to one month after&#xD;
      completion of the AC portion of cancer treatment.&#xD;
&#xD;
      CARDIAC MRI (CMR): Studies will be performed on a 3.0T scanner (Siemens) and will include&#xD;
      complete function and tissue characterization. CMR studies will be performed pre-therapy,&#xD;
      after completion of AC, and 2 years after completion of AC. After de-identification and&#xD;
      randomization, a research assistant blinded to all clinical data will perform all CMR&#xD;
      analysis using commercially available software.&#xD;
&#xD;
      ECHOCARDIOGRAPHY: Routine echocardiography studies will be performed at baseline,&#xD;
      post-anthracycline completion, and at 6 months, 1 year, and 2 years follow up.&#xD;
&#xD;
      SERUM BIOMARKERS: Blood work will be obtained on the day of baseline imaging, immediately&#xD;
      after each cycle of anthracycline, on the day of post treatment imaging, and at the 6 months,&#xD;
      1 year and 2 year follow up. At each time point, optional samples of bio-banking may be&#xD;
      collected. Blood sample collection will be done locally at the participant's respective site&#xD;
      and transferred to University Health Network (UHN) biobank for future analysis or analysis of&#xD;
      markers that are not available at all sites (e.g. high sensitivity troponin I and BNP).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac MRI measured LVEF within 4 weeks of anthracycline completion</measure>
    <time_frame>Within 4 weeks of cancer therapy completion</time_frame>
    <description>Cardiac MRI LVEF at the end of treatment will be measured before cancer treatment and within 4 weeks after completion of anthracycline-based treatment. The pre-treatment measurement will facilitate a baseline adjusted comparison between placebo and statin treated groups.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Cardiac MRI measured LV end diastolic volume (LVEDV) and end systolic volume (LVESV) at the end of treatment</measure>
    <time_frame>Within 4 weeks of anthracycline completion</time_frame>
    <description>these measures will be obtained at the same time as the LVEF measures with pre-treatment measurements facilitating a baseline adjusted comparison between placebo and statin treated groups</description>
  </other_outcome>
  <other_outcome>
    <measure>The incidence of cardiotoxicity</measure>
    <time_frame>From start of anthracycline therapy to upto 4 weeks of anthracycline completion</time_frame>
    <description>defined by LVEF fall &gt;10% from pre-cancer treatment assessment to &lt;53%</description>
  </other_outcome>
  <other_outcome>
    <measure>Interruption of study drug due to side effects or permanent cessation of study drug or cancer treatment due to cardiac dysfunction</measure>
    <time_frame>From start of anthracycline therapy to upto 4 weeks of anthracycline completion</time_frame>
    <description>as defined by reduction in drug dose or delay of cancer treatment by more than 1 week or permanent cessation</description>
  </other_outcome>
  <other_outcome>
    <measure>Troponin I</measure>
    <time_frame>Maximal increase in Troponin I between pre-anthracycline therapy to within 4 weeks of anthracycline completion</time_frame>
    <description>Maximal increase in troponin I</description>
  </other_outcome>
  <other_outcome>
    <measure>BNP</measure>
    <time_frame>From start of anthracycline therapy to within 4 weeks of cancer therapy completion</time_frame>
    <description>Maximal increase in BNP</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial strain</measure>
    <time_frame>From start of anthracycline therapy to within 4 weeks of cancer therapy completion</time_frame>
    <description>Maximal change in myocardial strain</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI tissue characterization parameters</measure>
    <time_frame>Within 4 weeks of anthracycline completion</time_frame>
    <description>Maximal change in myocardial tissue characterization parameters as measured by cardiac MRI from pre-anthracycline treatment to within 4 weeks of anthracycline completion</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Cancer</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiotoxicity</condition>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 40mg OD</description>
    <arm_group_label>Statin</arm_group_label>
    <other_name>Statin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with one of the following malignancies requiring anthracycline based&#xD;
             chemotherapy with a curative intent: breast cancer; aggressive lymphomas; leukemia&#xD;
             (acute myelogenous leukemia, acute lymphoblastic leukemia, mixed phenotype acute&#xD;
             leukemia) or; sarcoma&#xD;
&#xD;
          2. Patients with high cardiovascular risk defined as:&#xD;
&#xD;
             I. ≥60 years and at least one of the following:&#xD;
&#xD;
             i. Compromised cardiac function based on baseline LVEF &lt;55% measured by&#xD;
             echocardiography or MUGA or moderate left sided valvular heart disease (moderate&#xD;
             mitral or aortic regurgitation or stenosis) ii. Planned cumulative doxorubicin dose&#xD;
             equivalent 200mg/m² or more iii. Prior anthracycline therapy at any cumulative dose or&#xD;
             prior chest/mediastinal radiation therapy iv. Any one of hypertension, smoking,&#xD;
             obesity (BMI≥30), history of cardiomyopathy or heart failure but with recovered LVEF&#xD;
             to ≥ 50%&#xD;
&#xD;
             OR&#xD;
&#xD;
             II. Age &lt;60 years with one of the following:&#xD;
&#xD;
             i. and at least 2 of the risk factors listed above (I i-iv) ii. type 2 diabetes with&#xD;
             age &lt;40 iii. type 1 diabetes duration &lt;15 years&#xD;
&#xD;
             OR&#xD;
&#xD;
             III. High anthracycline dose defined as ≥250mg/m² of doxorubicin, ≥600mg/m²&#xD;
             epirubicin, or other isoequivalent dose&#xD;
&#xD;
          3. Living within geographic area conducive to repeated clinical and imaging follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in another clinical research study where randomization would be&#xD;
             unacceptable&#xD;
&#xD;
          2. Previous history of statin intolerance&#xD;
&#xD;
          3. Already on statin therapy or known statin indicated condition:&#xD;
&#xD;
             I. atherosclerosis i. myocardial infarction ii. acute coronary syndrome iii. stable&#xD;
             angina iv. documented coronary disease by angiography (&gt;10% stenosis) v. stroke vi.&#xD;
             TIA vii. documented carotid disease viii. peripheral arterial disease ix. claudication&#xD;
             and/or ABI &lt;0.9&#xD;
&#xD;
             II. abdominal aortic aneurysm (&gt;3.0cm or previous aneurysm surgery)&#xD;
&#xD;
             III. chronic kidney disease (&gt;3 months duration and ACR &gt;3.0mg/mmol or eGFR&#xD;
             &lt;60mL/min/1.73m²)&#xD;
&#xD;
          4. CK level &gt;3x upper limit of normal&#xD;
&#xD;
          5. Evidence of hepatic dysfunction (ALT level &gt;2x upper limit of normal)&#xD;
&#xD;
          6. On a drug that is a strong inhibitor of cytochrome P450 3A4 or may require such&#xD;
             treatment during the treatment period (because atorvastatin is metabolized by this&#xD;
             pathway)&#xD;
&#xD;
          7. Significant valvular heart disease defined as severe stenotic or regurgitant lesions&#xD;
             of any of the cardiac valves&#xD;
&#xD;
          8. Life expectancy less than 12 months&#xD;
&#xD;
          9. Contraindication to cardiac MRI (e.g. implanted pacemakers, ICDs, other implanted&#xD;
             ferromagnetic objects unsafe for cardiac MRI or will result in significant artifact,&#xD;
             eGFR &lt;30)&#xD;
&#xD;
         10. Creatinine &gt;177umol/L&#xD;
&#xD;
         11. Known history of uncontrolled hypothyroidism (TSH level &gt;1.5x upper limit of normal)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paaladinesh Thavendiranathan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eitan Amir</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tiffanie Kei</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>6594</phone_ext>
    <email>tiffanie.kei@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yobiga Thevakumaran</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>3472</phone_ext>
    <email>Yobiga.Thevakumaran@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paaladinesh Thavendiranathan</last_name>
      <phone>416-340-5326</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

